<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="07e2c55d-707f-4e3f-be0e-385da673b8ee"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use PYLERA safely and effectively. See full prescribing information for PYLERA.<br/>
      <br/> PYLERA<sup>®</sup> (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) capsules, for oral use <br/> Initial U.S. Approval: 2006</title>
   <effectiveTime value="20250407"/>
   <setId root="5cdacbf5-67be-42eb-bd54-8acc32ea1abc"/>
   <versionNumber value="3"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="028473634" root="1.3.6.1.4.1.519.1"/>
            <name>H2-Pharma, LLC</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="a0f7344b-bb63-4d7b-803c-baab58151f88"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20240430"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="61269-380" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>PYLERA</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, and TETRACYCLINE HYDROCHLORIDE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="140" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="R3O80H60KX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BISMUTH SUBCITRATE POTASSIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="ZS9CD1I8YE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>BISMUTH CATION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="125" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="140QMO216E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METRONIDAZOLE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="140QMO216E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METRONIDAZOLE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="125" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="P6R62377KV" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TETRACYCLINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="F8VB5M810T" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TETRACYCLINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="12" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="61269-380-12" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20231001"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA050786" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231001"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>opaque</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="22" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">Aptalis;BMT</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="BOX">
               <id root="faaaeb52-db9b-4e64-8e7c-645d9525b0ac"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>
                  <content styleCode="emphasis">WARNING: POTENTIAL FOR CARCINOGENICITY</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Metronidazole has been shown to be carcinogenic in mice and rats. It is unknown whether metronidazole is associated with carcinogenicity in humans <content styleCode="italics">[see <linkHtml href="#S5.1">Warning and Precautions (5.1)</linkHtml>].</content>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250410"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>WARNING: POTENTIAL FOR CARCINOGENICITY</paragraph>
                        <paragraph>
                           <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Metronidazole has been shown to be carcinogenic in mice and rats. It is unknown whether metronidazole is associated with carcinogenicity in humans (<linkHtml href="#S5.1">5.1</linkHtml>).</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="fed5c6a1-43e2-43c2-b2b4-8c4811bf1132"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250410"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%">
                           <colgroup>
                              <col width="90%" align="left" valign="top"/>
                              <col width="10%" align="right" valign="top"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td align="left">Warnings and Precautions, Severe Cutaneous Adverse Reactions (<linkHtml href="#S5.5">5.5</linkHtml>)</td>
                                 <td align="right">3/2025</td>
                              </tr>
                              <tr>
                                 <td align="left">Contraindications, Methoxyflurane (<linkHtml href="#S4.2">4.1</linkHtml>)</td>
                                 <td align="right">Removed 3/2025</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="516c9e59-9947-4740-bffe-aff7c294970c"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20250407"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>PYLERA is a combination of metronidazole, a nitroimidazole antimicrobial, tetracycline,- a tetracycline class antimicrobial and bismuth subcitrate potassium, indicated for use, in combination with omeprazole, for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori. (<linkHtml href="#S1.1">1.1</linkHtml>)</paragraph>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of PYLERA and other antibacterial drugs, PYLERA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (<linkHtml href="#S1.2">1.2</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S1.1">
                     <id root="2a88ddec-0f03-4c05-b80c-7174f76b922a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1	Eradication of <content styleCode="italics">Helicobacter pylori</content> in Patients with Active Duodenal Ulcer or History of Duodenal Ulcer Disease</title>
                     <text>
                        <paragraph>PYLERA in combination with omeprazole are indicated for the treatment of patients with <content styleCode="italics">Helicobacter pylori</content> infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate <content styleCode="italics">H. pylori</content>.  The eradication of <content styleCode="italics">Helicobacter pylori</content> has been shown to reduce the risk of duodenal ulcer recurrence.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.2">
                     <id root="f8b77aac-1656-44d7-80b4-04d0cbf999b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2	Usage</title>
                     <text>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of PYLERA and other antibacterial drugs, PYLERA should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria.  When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="c5454d78-edc1-46a4-89d5-33b11c38aff3"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Administer three PYLERA capsules 4 times a day (after meals and at bedtime) for 10 days.  One omeprazole 20 mg capsule should be taken twice a day with PYLERA after the morning and evening meal for 10 days (<content styleCode="bold">Table 1</content>).</paragraph>
                  <table width="80%">
                     <caption>Table 1: Daily Dosing Schedule for PYLERA</caption>
                     <col width="33%" align="left" valign="top"/>
                     <col width="34%" align="center" valign="top"/>
                     <col width="33%" align="center" valign="top"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Rrule">Time of dose</th>
                           <th styleCode="Rrule">Number of capsules of PYLERA</th>
                           <th styleCode="Rrule">Number of capsules of omeprazole 20 mg</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">After morning meal</td>
                           <td styleCode="Rrule">3</td>
                           <td styleCode="Rrule">1</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">After lunch</td>
                           <td styleCode="Rrule">3</td>
                           <td styleCode="Rrule">0</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">After evening meal</td>
                           <td styleCode="Rrule">3</td>
                           <td styleCode="Rrule">1</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule">At bedtime</td>
                           <td styleCode="Rrule">3</td>
                           <td styleCode="Rrule">0</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Instruct patients to swallow the PYLERA capsules whole with a full glass of water (8 ounces).  Ingestion of adequate amounts of fluid, particularly with the bedtime dose, is recommended to reduce the risk of esophageal irritation and ulceration by tetracycline hydrochloride.</paragraph>
                  <paragraph>If a dose is missed, patients should continue the normal dosing schedule until medication is gone.  Patients should not take double doses. If more than 4 doses are missed, the prescriber should be contacted.</paragraph>
               </text>
               <effectiveTime value="20250407"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Administer three PYLERA capsules 4 times a day (after meals and at bedtime) for 10 days. (<linkHtml href="#S2">2</linkHtml>)</item>
                           <item>Administer PYLERA with omeprazole 20 mg twice daily (after the morning and evening meals). (<linkHtml href="#S2">2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="4d8d0a2c-9f45-437f-b3f6-bc9e9f4fac99"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Each PYLERA capsule contains 140 mg of bismuth subcitrate potassium, 125 mg of metronidazole, and a smaller capsule inside containing 125 mg of tetracycline hydrochloride. The capsules are white and opaque, with the APTALIS<sub>™</sub> logo printed on the body and "BMT" printed on the cap.</paragraph>
               </text>
               <effectiveTime value="20250407"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Each capsule of PYLERA contains: (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>140 mg of bismuth subcitrate potassium</item>
                           <item>125 mg metronidazole</item>
                           <item>125 mg of tetracycline hydrochloride</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="26c48a33-3476-45b1-991a-80065916a7d2"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <effectiveTime value="20250407"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Disulfiram usage within the last two weeks. (<linkHtml href="#S4.2">4.1</linkHtml>, <linkHtml href="#S7.2">7.1</linkHtml>)</item>
                           <item>Alcoholic beverage consumption for at least three days during or after therapy. (<linkHtml href="#S4.3">4.2</linkHtml>, <linkHtml href="#S7.3">7.2</linkHtml>)</item>
                           <item>Patients with Cockayne syndrome. (<linkHtml href="#S4.4">4.3</linkHtml>, <linkHtml href="#S6.3">6.3</linkHtml>)</item>
                           <item>Severe renal impairment. (<linkHtml href="#S4.5">4.4</linkHtml>)</item>
                           <item>Women who are pregnant. (<linkHtml href="#S4.6">4.5</linkHtml>, <linkHtml href="#S8.1">8.1</linkHtml>)</item>
                           <item>Known hypersensitivity to product components. (<linkHtml href="#S4.7">4.6</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S4.2">
                     <id root="ae873bdb-f5ae-4f79-a189-1a7822f07a04"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.1 Disulfiram</title>
                     <text>
                        <paragraph>PYLERA is contraindicated in patients who have taken disulfiram within the last two weeks. Psychotic reactions have been reported in alcoholic patients who are using metronidazole, a component of PYLERA, and disulfiram concurrently <content styleCode="italics">[see <linkHtml href="#S7.2">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="S4.3">
                     <id root="3d056a1f-95be-41c5-a966-55eb5fec78a4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.2 Alcohol</title>
                     <text>
                        <paragraph>Alcoholic beverages or other products containing propylene glycol should not be consumed during and for at least 3 days after therapy with PYLERA. A disulfiram-like reaction (abdominal cramps, nausea, vomiting, headaches, and flushing) may occur due to the interaction between alcohol or propylene glycol and metronidazole, a component of PYLERA <content styleCode="italics">[see <linkHtml href="#S7.3">Drug Interactions (7.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="S4.4">
                     <id root="7220b292-cd92-47c7-94c5-1dfc8b6fa7e5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.3 Cockayne Syndrome</title>
                     <text>
                        <paragraph>									PYLERA is contraindicated in patients with Cockayne syndrome. Severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after initiation of metronidazole in patients with Cockayne syndrome <content styleCode="italics">[see <linkHtml href="#S6.3">Adverse Reactions (6.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="S4.5">
                     <id root="05b4b0b0-72b1-4dab-9580-adac5bd328c1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.4 Severe Renal Impairment</title>
                     <text>
                        <paragraph>PYLERA is contraindicated in patients with severe renal impairment.  The antianabolic action of the tetracyclines may cause an increase in blood urea nitrogen (BUN) <content styleCode="italics">[see <linkHtml href="#S6.3">Adverse Reactions (6.3)</linkHtml>]</content>. In patients with significantly impaired renal function, higher serum concentrations of tetracyclines may lead to azotemia, hyperphosphatemia, and acidosis.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="S4.6">
                     <id root="642d34e8-21b3-4b37-aa42-e7b157286a39"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.5 Pregnancy</title>
                     <text>
                        <paragraph>PYLERA is contraindicated during pregnancy <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="S4.7">
                     <id root="e9a5d59c-2242-49ae-bc02-4b253ee5d1ae"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.6 Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>PYLERA is contraindicated in patients with known hypersensitivity (e.g. urticaria, erythematous rash, flushing, and fever) to bismuth subcitrate potassium, metronidazole or other nitroimidazole derivatives, or tetracycline <content styleCode="italics">[see <linkHtml href="#S6.3">Adverse Reactions (6.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="460551fb-8d08-4535-b020-6aaa1c2666c1"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250407"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Fetal Toxicity: Advise pregnant women of the risk throughout pregnancy for retardation of skeletal development seen in animal studies and permanent discoloration of teeth with tetracycline if used during the second or third trimester. (<linkHtml href="#S5.2">5.2</linkHtml>, <linkHtml href="#S8.1">8.1</linkHtml>)</item>
                           <item>Maternal Toxicity: Risk of hepatotoxicity in pregnant women with high doses of intravenous tetracycline also resulting in stillborn or premature birth. (<linkHtml href="#S5.3">5.3</linkHtml>, <linkHtml href="#S8.1">8.1</linkHtml>)</item>
                           <item>Tooth Enamel discoloration and hypoplasia: permanent discoloration may develop with use during tooth development (last half of pregnancy, infancy, and childhood to the age of 8 years). (<linkHtml href="#S5.4">5.4</linkHtml>)</item>
                           <item>Severe Cutaneous Adverse Reactions: Severe cutaneous adverse reactions (SCARs) including toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP) have been reported with metronidazole. If symptoms or signs of SCARs develop, discontinue PYLERA immediately and institute appropriate therapy. (<linkHtml href="#S5.5">5.5</linkHtml>)</item>
                           <item>Central and Peripheral Nervous System Effects: encephalopathy, convulsive seizures, aseptic meningitis and peripheral neuropathy with metronidazole, intracranial hypertension with tetracycline and neurotoxicity with bismuth-containing products. Monitor patients with CNS conditions closely and discontinue promptly if abnormal neurologic signs develop. (<linkHtml href="#S5.6">5.6</linkHtml>)</item>
                           <item>Photosensitivity: avoid exposure to sun and sun lamps. (<linkHtml href="#S5.8">5.8</linkHtml>)</item>
                           <item>Blood Dyscrasias: Use with caution in patients with a history of blood dyscrasias. (<linkHtml href="#S5.10">5.10</linkHtml>)</item>
                           <item>Hepatic Impairment: Not recommended in patients with severe hepatic impairment. (<linkHtml href="#S5.11">5.11</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="6dfa856d-81d3-4a09-af49-69420618ccfd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Potential for Carcinogenicity</title>
                     <text>
                        <paragraph>Metronidazole, a component of PYLERA, has been shown to be carcinogenic in mice and rats. Tumors affecting the liver, lungs, mammary and lymphatic tissues have been detected in several studies of metronidazole in rats and mice, but not hamsters <content styleCode="italics">[see <linkHtml href="#S13">Nonclinical Toxicology (13)</linkHtml>]</content>.  It is unknown whether metronidazole is associated with carcinogenicity in humans.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="3329fa25-9a34-4aa6-b8fc-b0dcfe5d5a85"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	Fetal Toxicity</title>
                     <text>
                        <paragraph>Tetracycline can cause fetal harm when administered to a pregnant woman. Based on animal data, use of drugs of the tetracycline class during the second and third trimester of pregnancy can cause permanent discoloration of the teeth (yellow-gray brown) and possibly inhibit bone development <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>. Administration of oral tetracycline to pregnant rats at various doses resulted in yellow fluorescence in teeth and bones in the newborn animals. If PYLERA is used during pregnancy, or if the patient becomes pregnant while taking PYLERA, advise the patient of the potential risk to the fetus <content styleCode="italics">[see <linkHtml href="#S4.6">Contraindications (4.5)</linkHtml> and <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="e5559178-50b9-4065-be61-e31b23075848"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Maternal Toxicity</title>
                     <text>
                        <paragraph>Tetracycline, a component of PYLERA, administered during pregnancy at high doses (&gt; 2 g IV) was associated with rare but serious cases of maternal hepatotoxicity. This syndrome may result in stillborn or premature birth due to maternal pathology <content styleCode="italics">[see <linkHtml href="#S4.6">Contraindications (4.5)</linkHtml> and <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="f1b0ade3-1648-4091-86d4-359f742ba103"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4	Tooth Enamel Discoloration and Hypoplasia</title>
                     <text>
                        <paragraph>The use of drugs of the tetracycline class during tooth development (last half of pregnancy, infancy, and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown).  This adverse reaction is more common during long-term use of the drug, but has been observed following repeated short-term courses.  Enamel hypoplasia has also been reported. PYLERA, therefore, should not be used in this age group unless other drugs are not likely to be effective or are contraindicated <content styleCode="italics">[see <linkHtml href="#S8.4">Use in Specific Populations (8.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="e60d625b-5f49-4958-9ec4-6cd36c6770af"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5	Severe Cutaneous Adverse Reactions</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="underline">Metronidazole</content>: Severe cutaneous adverse reactions (SCARs) including toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP) have been reported with the use of metronidazole. Symptoms can be serious and potentially life threatening. If symptoms or signs of SCARs develop, discontinue PYLERA capsules immediately and institute appropriate therapy.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="underline">Tetracycline</content>: Fixed drug eruptions have occurred with tetracycline and have been associated with worsening severity upon subsequent<br/>administrations, including generalize bullous fixed drug eruption <content styleCode="italics">[see <linkHtml href="#S6.3">Adverse Reactions (6.3)</linkHtml>]</content>. If severe skin reactions occur,<br/>discontinue PYLERA immediately, and institute appropriate therapy.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="e30a9458-b82a-4b53-be16-8f8973279e3e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6	Central and Peripheral Nervous System Effects</title>
                     <effectiveTime value="20240430"/>
                     <component>
                        <section>
                           <id root="4f40061a-1970-4d7c-806e-d86091510cb8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Metronidazole</content>: Convulsive seizures, encephalopathy, aseptic meningitis and peripheral neuropathy (including optic neuropathy) have been reported. Encephalopathy has been reported in association with cerebellar toxicity characterized by ataxia, dizziness, and dysarthria.  CNS lesions seen on MRI have been described in reports of encephalopathy.  CNS symptoms are generally reversible within days to weeks upon discontinuation of metronidazole. CNS lesions seen on MRI have also been described as reversible. Peripheral neuropathy, mainly of sensory type has been reported and is characterized by numbness or paresthesia of an extremity. Aseptic meningitis symptoms may occur within hours of dose administration and generally resolve after metronidazole therapy is discontinued.</paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="ce35424e-8b69-41c3-8479-3cb27fb2103f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Tetracycline</content>: Intracranial hypertension (IH), including pseudotumor cerebri, has been associated with the use of tetracyclines. Clinical manifestations of IH include headache, blurred vision, diplopia, and vision loss; papilledema can be found on fundoscopy. Women of childbearing age who are overweight or have a history of IH are at greater risk for developing tetracycline associated IH. Concomitant use of isotretinoin should be avoided because isotretinoin is also known to cause IH.</paragraph>
                              <paragraph>Although IH typically resolves after discontinuation of treatment, the possibility for permanent visual loss exists. If visual disturbance occurs during treatment, prompt ophthalmologic evaluation is warranted. Since intracranial pressure can remain elevated for weeks after drug cessation, patients should be monitored until they stabilize.</paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="ff3c90a4-7b89-4fb2-8889-2854dce445f6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>Bismuth-containing products: Cases of neurotoxicity associated with excessive doses of various bismuth-containing products have been reported. Effects have been reversible with discontinuation of bismuth therapy.</paragraph>
                              <paragraph>The appearance of abnormal neurologic signs and symptoms demands the prompt evaluation of the benefit/risk ratio of the continuation of PYLERA therapy <content styleCode="italics">[see <linkHtml href="#S6.3">Adverse Reactions (6.3)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="2ee85ef9-64ed-4f68-925b-4eac7c3e0d61"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7	Development of Potential for Microbial Overgrowth</title>
                     <text>
                        <paragraph>Known or previously unrecognized candidiasis may present more prominent symptoms during therapy with metronidazole and requires treatment with an antifungal agent. As with other antibacterial drugs, use of tetracycline hydrochloride may result in overgrowth of nonsusceptible organisms, including fungi.  If superinfection occurs, discontinue PYLERA and institute appropriate therapy.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.8">
                     <id root="898414fa-79df-4eab-a365-db87c5a1da33"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8	Photosensitivity</title>
                     <text>
                        <paragraph>Photosensitivity, manifested by an exaggerated sunburn reaction, has been observed in patients taking tetracycline <content styleCode="italics">[see <linkHtml href="#S6.3">Adverse Reactions (6.3)</linkHtml>]</content>.  Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs.  Instruct patients taking PYLERA to avoid exposure to the sun or sun lamps.  Discontinue treatment at the first evidence of skin erythema.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.9">
                     <id root="1bf989c0-864f-4378-84d8-720f70e4e06d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9	Darkening of the Tongue and/or Black Stool</title>
                     <text>
                        <paragraph>Bismuth subcitrate potassium may cause temporary and harmless darkening of the tongue and/or black stools, generally reversible within several days after treatment is stopped <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>.  Stool darkening should not be confused with melena.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.10">
                     <id root="916a866d-7dfb-46f2-bb99-9ce96ddac334"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10	Use in Patients with Blood Dyscrasias</title>
                     <text>
                        <paragraph>Metronidazole is a nitroimidazole, and should be used with care in patients with evidence of or history of blood dyscrasia. A mild leukopenia has been observed during its administration; however, no persistent hematologic abnormalities attributable to metronidazole have been observed in clinical studies. Total and differential leukocyte counts are recommended before and after therapy <content styleCode="italics">[see <linkHtml href="#S6.3">Adverse Reactions (6.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.11">
                     <id root="bfaee14c-497c-44be-9116-99edb077d5c4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.11	Increased Drug Plasma Concentrations in Patients with Hepatic Impairment</title>
                     <text>
                        <paragraph>Patients with hepatic impairment metabolize metronidazole slowly, with resultant accumulation of metronidazole in the plasma. Patients with mild to moderate hepatic impairment should be monitored for metronidazole associated adverse events. PYLERA is not recommended in patients with severe hepatic impairment (Child-Pugh C) <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.12">
                     <id root="a84ccccd-c0a7-4a58-acde-dea5b1836762"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.12	Laboratory Test Interactions</title>
                     <text>
                        <paragraph>Bismuth absorbs x-rays and may interfere with x-ray diagnostic procedures of the gastrointestinal tract.</paragraph>
                        <paragraph>Bismuth subcitrate potassium may cause a temporary and harmless darkening of the stool.  However, this change does not interfere with standard tests for occult blood.</paragraph>
                        <paragraph>Metronidazole may interfere with certain types of determinations of serum chemistry values, such as aspartate aminotransferase (AST, SGOT), alanine aminotransferase (ALT, SGPT), lactate dehydrogenase (LDH), triglycerides, and hexokinase glucose.  Values of zero may be observed.  All of the assays in which interference has been reported involve enzymatic coupling of the assay to oxidation-reduction of nicotinamide (NAD+ &lt;=&gt; NADH). Interference is due to the similarity in absorbance peaks of NADH (340 nm) and metronidazole (322 nm) at pH 7.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.13">
                     <id root="26de0a3a-f684-4375-8c48-d1a4e3d4a4c1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.13	Development of Drug Resistant Bacteria</title>
                     <text>
                        <paragraph>Prescribing PYLERA in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.14">
                     <id root="6d533136-aa90-4fce-a947-31845a2b282e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.14	Drug Interactions</title>
                     <effectiveTime value="20250407"/>
                     <component>
                        <section>
                           <id root="9b1d6111-a579-45b1-9d56-bfc72177466f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">
                                    <content styleCode="xmChange">Oral Contraceptives</content>
                                 </content>
                              </paragraph>
                              <paragraph>Concurrent use of PYLERA with oral contraceptive may make oral contraceptives less effective due to an interaction with the tetracycline component of PYLERA. Breakthrough bleeding has been reported. Advise women of child-bearing potential to use a different or additional form of contraception while taking PYLERA <content styleCode="italics">[see <linkHtml href="#S7.4">Drug Interactions (7.3)</linkHtml>]</content>
                                 <content styleCode="xmChange">.</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250407"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="11a3d283-eca4-4979-b01d-8704116b8a66"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Anticoagulants</content>
                              </paragraph>
                              <paragraph>PYLERA may alter the anticoagulant effects of warfarin and other oral coumarin anticoagulants. Metronidazole has been reported to potentiate the anticoagulant effect of warfarin, and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. Tetracycline has been shown to depress plasma prothrombin activity. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if PYLERA is administered concomitantly with warfarin. Patients should also be monitored for evidence of bleeding <content styleCode="italics">[see <linkHtml href="#S7.5">Drug Interactions (7.4)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250407"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="055dafee-c33c-4244-b0e2-72aad3bc98c6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Lithium</content>
                              </paragraph>
                              <paragraph>In patients stabilized on relatively high doses of lithium, short-term use of PYLERA may cause elevation of serum lithium concentrations and signs of lithium toxicity due to the interaction between metronidazole and lithium. Monitor serum lithium and serum creatinine concentrations daily for several days after beginning treatment with PYLERA to detect any increase that may precede clinical symptoms of lithium toxicity <content styleCode="italics">[see <linkHtml href="#S7.6">Drug Interactions (7.5)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250407"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="7f88974c-dac4-4ef4-b1c9-c4c259e16a80"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Busulfan</content>
                              </paragraph>
                              <paragraph>Metronidazole has been reported to increase plasma concentrations of busulfan, which can result in an increased risk for serious busulfan toxicity. Do not administer PYLERA concomitantly with busulfan unless the benefit outweighs the risk. If no therapeutic alternatives to PYLERA are available, and concomitant administration with busulfan is medically needed, monitor for busulfan toxicity and busulfan plasma concentrations and adjust the busulfan dose accordingly <content styleCode="italics">[see <linkHtml href="#S7.8">Drug Interactions (7.7)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250407"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="20782c46-b9c1-4fb7-a7bb-f828b06b2d1a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drugs that Prolong the QT interval</content>
                              </paragraph>
                              <paragraph>											QT prolongation has been reported with metronidazole, a component of PYLERA, particularly when administered with drugs with the potential for prolonging the QT interval. 										</paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="c258a0d0-f5c0-4c15-9403-463e7c58b94e"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20250407"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most frequently reported adverse reactions (≥5%): abnormal feces, diarrhea, nausea, and headache. (<linkHtml href="#S6.1">6.1</linkHtml>)</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact H2-Pharma, LLC at 1-833-520-8580 or FDA at 1-800-FDA-1088 or <content styleCode="italics">www.fda.gov/medwatch.</content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="e6f3f0cb-e740-46ff-91bc-230878a60a72"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The safety of PYLERA plus omeprazole (OBMT) to eradicate <content styleCode="italics">Helicobacter pylori</content> was assessed in an open-label, randomized, active-controlled clinical trial conducted in North America. The duration of treatment was 10 days with 147 patients exposed to PYLERA plus omeprazole (OBMT) and 152 exposed to control, consisting of omeprazole, amoxicillin, and clarithromycin (OAC). The age of the population in the study ranged from 18 to 75 years, with 59% male patients and 59% Caucasian patients.</paragraph>
                        <paragraph>Adverse drug reactions were reported in 58% of patients in the OBMT group and 59% of patients in the OAC group. There were no adverse reactions leading to discontinuation of the study during the clinical trial.</paragraph>
                        <paragraph>Adverse reactions with an incidence of ≥ 5% in OBMT group include abnormal feces, diarrhea, nausea, and headache. Adverse drug reactions with an incidence of ≥ 5% in OAC group include diarrhea, dysgeusia, dyspepsia, nausea and headache.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 2</content> lists adverse reactions with an incidence of ≥ 1%, in either group (OBMT vs OAC) and in order of decreasing incidence for the OBMT group.</paragraph>
                        <table width="100%">
                           <caption> Table 2: Adverse reactions with an incidence of ≥ 1% from North American trial, [n (%)]</caption>
                           <tfoot>
                              <tr styleCode="First Last" align="left">
                                 <td colspan="3">
                                    <paragraph>*OBMT = Omeprazole + PYLERA</paragraph>
                                    <paragraph>**OAC = Omeprazole + Amoxicillin + Clarithromycin;</paragraph>
                                    <paragraph>*** Dark stools <content styleCode="italics">[see <linkHtml href="#S5.9">Warnings and Precautions (5.9)</linkHtml>]</content>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Preferred Term</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">OBMT* (n = 147)</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">OAC** (n = 152)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="underline">
                                       <content styleCode="bold">Gastrointestinal disorders</content>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Abnormal feces***</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">23 (15.6%)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">7 (4.6%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Nausea</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">12 (8.2%)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">14 (9.2%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Diarrhea</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">10 (6.8%)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">20 (13.2%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Abdominal Pain</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">7 (4.8%)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">2 (1.3%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Dyspepsia</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">4 (2.7%)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">10 (6.6%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Constipation</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">2 (1.4%)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">5 (3.3%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Dry Mouth</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">2 (1.4%)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">1 (0.7%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Flatulence</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">0</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">4 (2.6%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Glossitis</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">0</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">2 (1.3%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="underline">
                                       <content styleCode="bold">General disorders and administration site conditions</content>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Asthenia</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">5 (3.4%)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">2 (1.3%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="underline">
                                       <content styleCode="bold">Infections and infestations</content>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Vaginal infection</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">4 (2.7%)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">3 (2.0%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="underline">
                                       <content styleCode="bold">Nervous system disorders</content>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Headache</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">8 (5.4%)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">8 (5.3%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Dysgeusia</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">6 (4.1%)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">18 (11.8%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Dizziness</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">4 (2.7%)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">4 (2.6%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="underline">
                                       <content styleCode="bold">Investigations</content>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Laboratory test abnormal</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">3 (2.0%)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">4 (2.6%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Alanine aminotransferase increased</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">2 (1.4%)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Aspartate aminotransferase increased</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">2 (1.4%)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="underline">
                                       <content styleCode="bold">Renal and urinary disorders</content>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Urine abnormality</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">2 (1.4%)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="underline">
                                       <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Rash Maculo-Papular</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">2 (1.4%)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Rash</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">1 (0.7%)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">3 (2.0%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Pruritus</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">0</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">4 (2.6%)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                        <paragraph>Adverse reactions with an incidence of &lt;1% for OBMT group are: back pain, vomiting, tongue darkening <content styleCode="italics">[see <linkHtml href="#S5.9">Warnings and Precautions (5.9)</linkHtml>]</content>, anxiety, gastritis, gastroenteritis, myalgia, chest pain, increased appetite, blood creatine phosphokinase increased, malaise, somnolence, tachycardia, duodenal ulcer, visual disturbance, weight increased.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="3f37e10c-26d7-47a4-93e9-8d7970ac6bf4"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>Additionally, the following adverse reactions, presented by system organ class in alphabetical order, have been identified during post approval use of PYLERA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="italics">Gastrointestinal disorders:</content> abdominal distention, eructation, flatulence</item>
                           <item>
                              <content styleCode="italics">General disorders and administration site conditions:</content> chest discomfort, fatigue</item>
                           <item>
                              <content styleCode="italics">Infections and infestations</content>: candidiasis, pseudomembranous colitis (<content styleCode="italics">Clostridium difficile</content> colitis) </item>
                           <item>
                              <content styleCode="italics">Nervous Systems:</content> peripheral neuropathy</item>
                           <item>
                              <content styleCode="italics">Skin and subcutaneous disorders:</content> Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS syndrome (drug rash with eosinophilia and systemic symptoms) [<content styleCode="italics">see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>
                              </content>]</item>
                        </list>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S6.3">
                     <id root="9b3c3ce8-ee3c-44e5-90f5-b04c7c3ad486"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.3	Other Important Adverse Reactions from Labeling for the Individual Components of PYLERA</title>
                     <effectiveTime value="20250407"/>
                     <component>
                        <section>
                           <id root="4af5da4b-d8ce-4a84-b71a-ea6cc2919256"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Metronidazole</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Blood and Lymphatic system disorders:</content> Reversible neutropenia (leucopenia) in cases of prolonged treatment; rarely reversible thrombocytopenia however no persistent hematological abnormalities attributable to metronidazole have been observed <content styleCode="italics">[see <linkHtml href="#S5.10">Warnings and Precautions (5.10)</linkHtml>]</content>.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Cardiac disorders:</content> QT prolongation has been reported with metronidazole, particularly when administered with drugs with the potential for prolonging the QT interval. Flattening of the T-wave may be seen in electrocardiographic tracings.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Gastrointestinal disorders:</content> Nausea, vomiting, diarrhea, abdominal pain, constipation, anorexia, metallic taste, furry tongue, glossitis, stomatitis and candida overgrowth.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Hypersensitivity/Immune system disorders:</content> Acute generalized exanthematous pustulosis (AGEP) <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>, urticaria, erythematous rash, flushing, nasal congestion, dryness of the mouth (or vagina or vulva), and fever <content styleCode="italics">[see <linkHtml href="#S4.7">Contraindications (4.6)</linkHtml>]</content>.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Metabolism and nutrition disorders:</content> Pancreatitis.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Nervous system disorders:</content> Convulsive seizures, encephalopathy, aseptic meningitis, optic and peripheral neuropathy, headache, syncope, dizziness, vertigo, incoordination, ataxia, tinnitus, hearing impairment, hearing loss, confusion, dysarthria, irritability, depression, weakness, and insomnia <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]</content>.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Dermatologic disorders:</content> Erythematous rash and pruritus.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Renal and urinary disorders:</content> Dysuria, cystitis, polyuria, incontinence, darkened urine, and a sense of pelvic pressure.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Hepatic:</content> Cases of severe irreversible hepatotoxicity/acute liver failure, including cases with fatal outcomes with very rapid onset after initiation of systemic use of metronidazole, have been reported in patients with Cockayne Syndrome (latency from drug start to signs of liver failure as short as 2 days) <content styleCode="italics">[see <linkHtml href="#S4.4">Contraindications (4.3)</linkHtml>]</content>.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Other:</content> Dyspareunia, decrease of libido, proctitis, joint pains.</paragraph>
                           </text>
                           <effectiveTime value="20250407"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="f6a47386-e55d-4d70-85f4-e768e74f8e65"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline"> Tetracycline Hydrochloride</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Blood and lymphatic system disorders:</content> Hemolytic anemia, thrombocytopenia, thrombocytopenic purpura, neutropenia, and eosinophilia.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Gastrointestinal disorders:</content> Nausea, vomiting, diarrhea, anorexia, glossitis, black hairy tongue, dysphagia, enterocolitis, inflammatory lesions (with Candida overgrowth) in the anogenital region, esophagitis and esophageal ulceration.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Nervous system disorders:</content> Intracranial hypertension including pseudotumor cerebri, tinnitus, and myasthenic syndrome.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Renal and urinary disorders:</content> Increased BUN.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Skin and subcutaneous tissue disorders: </content>
                                 <content styleCode="xmChange">Maculopapular and erythematous rashes, onycholysis, fixed drug eruption, discoloration of the nails, exfoliative dermatitis and photosensitivity have been rarely reported [see <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>].</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Liver:</content> Hepatotoxicity and liver failure.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Hypersensitivity reactions:</content> Urticaria, angioedema, anaphylaxis, Henoch-Schonlein purpura, pericarditis, exacerbation of systemic lupus erythematosus, and serum sickness-like reactions.</paragraph>
                           </text>
                           <effectiveTime value="20250407"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="c742c202-9dd6-49b9-aa48-1f576e06215b"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250407"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Disulfiram: Psychotic reactions can occur; do not take concurrently or within the last 2 weeks of disulfiram. (<linkHtml href="#S4.2">4.1</linkHtml>, <linkHtml href="#S7.2">7.1</linkHtml>)</item>
                           <item>Alcohol: Abdominal cramps, nausea, vomiting, headaches, and flushing can occur; do not consume during therapy and for at least 3 days afterwards. (<linkHtml href="#S4.3">4.2</linkHtml>, <linkHtml href="#S7.3">7.2</linkHtml>)</item>
                           <item>Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (<linkHtml href="#S5.14">5.14</linkHtml>, <linkHtml href="#S7.4">7.3</linkHtml>)</item>
                           <item>Anticoagulants: Potentiation of the anticoagulant effect; Prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests should be closely monitored. (<linkHtml href="#S5.14">5.14</linkHtml>, <linkHtml href="#S7.5">7.4</linkHtml>)</item>
                           <item>Lithium: Increased lithium serum concentrations; measure serum lithium and serum creatinine concentrations during therapy. (<linkHtml href="#S5.14">5.14</linkHtml>, <linkHtml href="#S7.6">7.5</linkHtml>)</item>
                           <item>Antacids, Multivitamins or Dairy Products: Decreased absorption of PYLERA; do not take concomitantly. (<linkHtml href="#S7.7">7.6</linkHtml>)</item>
                           <item>Busulfan: Increased busulfan serum concentrations; avoid concomitant use, monitor for busulfan toxicity. (<linkHtml href="#S7.8">7.7</linkHtml>)</item>
                           <item>CYP inducers and CYP inhibitors: Prolonged or accelerated half-life of metronidazole or concomitant medications; use with caution. (<linkHtml href="#S7.9">7.8</linkHtml>, <linkHtml href="#S7.10">7.9</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.2">
                     <id root="18435923-a643-42e1-8e5d-67400783d3a2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Disulfiram</title>
                     <text>
                        <paragraph>Psychotic reactions have been reported in alcoholic patients who are using metronidazole, a component of PYLERA and disulfiram concurrently. PYLERA should not be given to patients who have taken disulfiram within the last two weeks <content styleCode="italics">[see <linkHtml href="#S4.2">Contraindications (4.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.3">
                     <id root="1ca76776-c8de-4af3-896f-78e17729bce6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Alcohol</title>
                     <text>
                        <paragraph>Consumption of alcoholic beverages or administration of other products containing propylene glycol during treatment with PYLERA and for at least 3 days afterwards may cause a disulfiram-like reaction (abdominal cramps, nausea, vomiting, headaches, and flushing) due to the interaction between alcohol or propylene glycol and metronidazole, a component of PYLERA. Discontinue alcoholic beverage or other products containing propylene glycol during and for at least 3 days after therapy with PYLERA <content styleCode="italics">[see <linkHtml href="#S4.3">Contraindications (4.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.4">
                     <id root="8981d17e-e7d4-445f-8111-d67856fe5ef6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Oral Contraceptives</title>
                     <text>
                        <paragraph>Concurrent use of PYLERA with oral contraceptive may make oral contraceptives less effective due to an interaction with the tetracycline component of PYLERA.  Breakthrough bleeding has been reported.  Women of child-bearing potential should use a different or additional form of contraception while taking PYLERA <content styleCode="italics">[see <linkHtml href="#S5.14">Warnings and Precautions (5.14)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.5">
                     <id root="e286f2a3-68c3-41f1-bf18-f486ca1ad249"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4 Anticoagulants</title>
                     <text>
                        <paragraph>PYLERA may alter the anticoagulant effects of warfarin and other oral coumarin anticoagulants.  Metronidazole has been reported to potentiate the anticoagulant effect of warfarin, and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time.  Tetracycline has been shown to depress plasma prothrombin activity. Prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests should be closely monitored if PYLERA is administered concomitantly with warfarin. Patients should also be monitored for evidence of bleeding <content styleCode="italics">[see <linkHtml href="#S5.14">Warnings and Precautions (5.14)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.6">
                     <id root="03612e54-f55a-48df-afbe-8eff8182c078"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.5 Lithium</title>
                     <text>
                        <paragraph>In patients stabilized on relatively high doses of lithium, short-term use of PYLERA may cause elevation of serum lithium concentrations and signs of lithium toxicity due to the interaction between metronidazole and lithium.  Serum lithium and serum creatinine concentrations should be monitored several days after beginning treatment with PYLERA to detect any increase that may precede clinical symptoms of lithium toxicity <content styleCode="italics">[see <linkHtml href="#S5.14">Warnings and Precautions (5.14)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.7">
                     <id root="f7f638eb-f97a-4a08-8c3f-1e691c77e67d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.6 Antacids, Multivitamins, or Dairy Products</title>
                     <text>
                        <paragraph>The absorption of PYLERA may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline.  These products should not be consumed concomitantly with PYLERA.  However, the clinical significance of reduced tetracycline systemic exposure is unknown as the relative contribution of systemic versus local antimicrobial activity against <content styleCode="italics">Helicobacter pylori</content> has not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.8">
                     <id root="1ece59ca-be5f-4c4f-8a05-e74c5fe6603b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.7 Busulfan</title>
                     <text>
                        <paragraph>Metronidazole has been reported to increase plasma concentrations of busulfan, which can result in an increased risk for serious busulfan toxicity. Do not administer PYLERA concomitantly with busulfan unless the benefit outweighs the risk. If no therapeutic alternatives to PYLERA are available, and concomitant administration with busulfan is medically needed, monitor for busulfan toxicity and busulfan plasma concentrations and adjust the busulfan dose accordingly <content styleCode="italics">[see <linkHtml href="#S5.14">Warnings and Precautions (5.14)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.9">
                     <id root="0b03b415-2699-404d-8fbc-a651f39bfcee"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.8 Inhibitors of CYP450 liver enzymes</title>
                     <text>
                        <paragraph>The simultaneous administration of PYLERA and drugs that inhibit microsomal liver enzymes, such as cimetidine, may result in a prolonged half-life and decreased plasma clearance of metronidazole.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.10">
                     <id root="00c8446b-4062-4ec5-8f11-7d06a57daed7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.9 Inducers of CYP450 liver enzymes</title>
                     <text>
                        <paragraph>The simultaneous administration of PYLERA and drugs that induce microsomal liver enzymes, such as phenytoin or phenobarbital, may accelerate the elimination of metronidazole, resulting in reduced plasma concentrations of metronidazole.  Impaired clearance of phenytoin has also been reported in this situation. Monitor phenytoin concentrations during treatment with PYLERA.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="c7e932af-e914-44a2-8948-693f4b58d6e5"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250407"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Lactation: A woman should pump and discard human milk for the duration of PYLERA therapy, and for 2 days after therapy ends.  (<linkHtml href="#S8.2">8.2</linkHtml>)</item>
                           <item>Pediatric Use: Tetracycline may cause permanent discoloration of the teeth. Enamel hypoplasia has also been reported.  Do not use in children less than 8 years of age. (<linkHtml href="#S5.4">5.4</linkHtml>, <linkHtml href="#S8.4">8.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="7ee75c79-f32a-4602-9ede-cc6f90f345c8"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250407"/>
                     <component>
                        <section>
                           <id root="eaa4456f-330e-4347-8140-8b2980243f34"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>PYLERA is contraindicated in women who are pregnant because treatment of <content styleCode="italics">Helicobacter pylori</content> infection can be delayed in pregnant women, and the use of drugs of the tetracycline class during the second and third trimester pregnancy can also cause permanent discoloration of the teeth (yellow-gray brown) and possibly inhibit bone development <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml> and <linkHtml href="#data">Data</linkHtml>]</content>.  Administration of oral tetracycline to pregnant rats at various doses resulted in yellow fluorescence in teeth and bones in the newborn animals.  There are maternal risks with high intravenous doses of tetracycline <content styleCode="italics">[see <linkHtml href="#CC">Clinical Considerations</linkHtml>].</content>
                              </paragraph>
                              <paragraph>Metronidazole usage in pregnancy has been associated with certain congenital anomalies <content styleCode="italics">[see <linkHtml href="#data">Data</linkHtml>].</content>  In animals, no fetotoxicity was observed when metronidazole was orally administered to pregnant mice at approximately 5% of the indicated human dose.  There are no human or animal data on the use of bismuth subcitrate potassium during pregnancy.  Although there are data on the separate components, there are no available data on the use of PYLERA in pregnant women.</paragraph>
                           </text>
                           <effectiveTime value="20250407"/>
                        </section>
                     </component>
                     <component>
                        <section ID="CC">
                           <id root="9187c82a-3fa6-4a1f-8a5b-de32a597bf45"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                           <component>
                              <section>
                                 <id root="48a9894e-edc0-415d-b8c0-88a899292293"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Maternal Adverse Reactions</content>
                                    </paragraph>
                                    <paragraph>Tetracycline administered during pregnancy at high doses (&gt; 2 g IV) was associated with rare but serious cases of maternal hepatotoxicity. This syndrome may result in stillborn or premature birth due to maternal pathology <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>].</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20240430"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="f513c878-1122-4ace-bfaf-380305bdf5ef"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                           <component>
                              <section>
                                 <id root="4aa1588e-247b-41ba-931f-b7a751680ce4"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Human Data</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20240430"/>
                                 <component>
                                    <section>
                                       <id root="d09646d5-636b-4c61-bafe-816c25a6d79f"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="underline">Tetracycline</content>
                                          </paragraph>
                                          <paragraph>Published case reports have described the yellowing of bones and teeth in human infants exposed to tetracycline during the second and third trimester of pregnancy. The yellowing is caused by the direct deposition of tetracycline during the mineralization process. This discoloration is more common during long-term use of the drug but has also been observed following repeated short-term courses. All tetracyclines form a stable calcium complex in any bone forming tissue. A decrease in fibula growth rate was observed in premature infants given oral tetracycline in doses of 25 mg/kg every six hours. The effect resolved when the drug was discontinued. One long-term follow-up study in children exposed to tetracycline in-utero showed no adverse effects on bone growth and development.</paragraph>
                                       </text>
                                       <effectiveTime value="20240430"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="deeee2ee-e577-44c9-aadb-c8d8aa06b433"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="underline">Metronidazole</content>
                                          </paragraph>
                                          <paragraph>There are published data from case-control studies, cohort studies, and 2 meta-analyses that include more than 5000 pregnant women who used metronidazole during pregnancy. Many studies included first trimester exposures. One study showed an increased risk of cleft lip, with or without cleft palate, in infants exposed to metronidazole in-utero; however, these findings were not confirmed. In addition, more than ten randomized, placebo-controlled clinical trials enrolled more than 5000 pregnant women to assess the use of antibiotic treatment (including metronidazole) for bacterial vaginosis on the incidence of preterm delivery. Most studies did not show an increased risk for congenital anomalies or other adverse fetal outcomes following metronidazole exposure during pregnancy. Three studies conducted to assess the risk of infant cancer following metronidazole exposure during pregnancy did not show an increased risk; however, the ability of these studies to detect such a signal was limited.</paragraph>
                                       </text>
                                       <effectiveTime value="20240430"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="8cbc69ca-8741-4691-8eaa-d8971e278ff1"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="underline">Bismuth subcitrate potassium</content>
                                          </paragraph>
                                          <paragraph>There are no human data on the use of bismuth subcitrate potassium during pregnancy.</paragraph>
                                       </text>
                                       <effectiveTime value="20240430"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="2b581fa1-0460-48ef-b46d-8d9e1dd81a6e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20240430"/>
                                 <component>
                                    <section>
                                       <id root="e52312d0-1600-4a02-b989-4ba5bfd5c246"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="underline">Tetracycline</content>
                                          </paragraph>
                                          <paragraph>Results of animal studies indicate that tetracycline crosses the placenta, is found in fetal tissues, and can have toxic effects on the developing fetus (often related to reversible retardation of skeletal development).  Evidence of embryotoxicity has also been noted in animals treated early in pregnancy. Multiple studies of limited design were conducted with pregnant and lactating female rats that resulted in fetuses and neonates with yellow discoloration of bones and teeth.</paragraph>
                                       </text>
                                       <effectiveTime value="20240430"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="5c7ae8f1-5729-41c7-930d-b5b52950e604"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="underline">Metronidazole</content>
                                          </paragraph>
                                          <paragraph>Metronidazole crosses the placental barrier.  No fetotoxicity was observed when metronidazole was administered orally to pregnant mice at 10 mg/kg/day, approximately 5 percent of the indicated human dose (1500 mg/day) based on body surface area; however in a single small study where the drug was administered intraperitoneally, some intrauterine deaths were observed.  The relationship of these findings to the drug is unknown.</paragraph>
                                       </text>
                                       <effectiveTime value="20240430"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="995b6e65-2c89-43fd-93e7-779bf53783b2"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="underline">Bismuth subcitrate potassium</content>
                                          </paragraph>
                                          <paragraph>Animal reproductive studies have not been conducted with bismuth subcitrate potassium.</paragraph>
                                       </text>
                                       <effectiveTime value="20240430"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="af396e36-d152-403c-90ba-467b055775ec"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20240430"/>
                     <component>
                        <section>
                           <id root="8d7b5dcd-06af-4a60-97d2-9813c997889c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Two of the individual components of PYLERA, tetracycline and metronidazole, are present in human milk at concentrations similar to maternal serum levels.  It is not known whether bismuth subcitrate, the third component of PYLERA is present in human milk. It is not known what effect metronidazole, tetracycline or bismuth has on the breastfed infant or on milk production.  Tetracycline binds with calcium in human milk <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>  Data indicate that oral absorption of tetracycline in infants is low due to the calcium binding in human milk.  Metronidazole transfers to human milk, and infant serum levels can be close to or comparable to infant therapeutic levels.  Because of the potential risk of tumorigenicity shown in animal studies with metronidazole, a woman should pump and discard human milk for the duration of PYLERA therapy, and for 2 days after therapy ends, and feed her infant stored human milk (collected prior to therapy) or formula.</paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="bc6408e4-4309-4965-9118-6265e0380ef1"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness of PYLERA in pediatric patients infected with <content styleCode="italics">Helicobacter pylori</content> have not been established.</paragraph>
                        <paragraph>Tetracycline use in children may cause permanent discoloration of the teeth. Enamel hypoplasia has also been reported.  PYLERA should not be used in children up to 8 years of age <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precaution (5.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="c2b10980-e2a1-4229-ab7b-8c715fbdf6f5"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of PYLERA did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, elderly patients may have a greater frequency of decreased hepatic, renal, or cardiac function, and concomitant diseases or other drug therapies. Bismuth subcitrate potassium, a component of PYLERA, is known to be substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, additional monitoring may be required <content styleCode="italics">[see <linkHtml href="#S4.5">Contraindications (4.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="95d3b8c4-8f7b-485a-8d8f-36c9f877dbcb"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>The antianabolic action of the tetracyclines may cause an increase in blood urea nitrogen (BUN). In patients with severe renal impairment, higher serum concentrations of tetracycline may lead to azotemia, hyperphosphatemia, and acidosis <content styleCode="italics">[see <linkHtml href="#S4.5">Contraindications (4.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="ad1b9104-326a-4a92-99d1-917dbe5b40a6"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph>Patients with severe hepatic disease metabolize metronidazole slowly, with resultant accumulation of metronidazole and its metabolites in plasma. Patients with mild to moderate hepatic impairment should be monitored for metronidazole associated adverse events. PYLERA is not recommended in patients with severe hepatic impairment <content styleCode="italics">[see <linkHtml href="#S5.11">Warnings and Precautions (5.11)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>
                           </content>]<content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="3f7b8f37-e80b-4429-9d9a-994b6059646d"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>In case of an overdose, patients should contact a physician, poison control center, or emergency room.  The available overdosage information for each of the individual components in PYLERA (Metronidazole, Tetracycline and Bismuth subcitrate potassium) are summarized below:</paragraph>
               </text>
               <effectiveTime value="20240430"/>
               <component>
                  <section>
                     <id root="df1151d2-c888-4d28-ba27-5ab0d5baaa4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Metronidazole:</content>
                        </paragraph>
                        <paragraph>Single oral doses of metronidazole, up to 15 g, have been reported in suicide attempts and accidental overdoses. Symptoms reported include nausea, vomiting, and ataxia. Metronidazole is dialyzable.</paragraph>
                        <paragraph>Neurotoxic effects, including seizures and peripheral neuropathy, have been reported after 5 to 7 days of doses of 6 to 10.4 g every other day.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                     <component>
                        <section>
                           <id root="abcad315-6c21-4fb9-b3b5-a96833050eaf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Treatment of Overdosage</content>
                              </paragraph>
                              <paragraph>There is no specific antidote for metronidazole overdose; therefore, management of the patient should consist of symptomatic and supportive therapy.</paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="93b76eaf-23ff-4cfe-999a-71af7a37151d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Tetracycline:</content>
                        </paragraph>
                        <paragraph>In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Dialysis does not alter serum half-life and thus would not be of benefit in treating cases of overdosage.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="5309b0a4-a589-4c86-9743-19b002582ca7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Bismuth subcitrate potassium:</content>
                        </paragraph>
                        <paragraph>Symptoms of a bismuth subcitrate potassium overdosage are not known.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="bd0cc641-b154-49c7-a36b-daadcc2655b4"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>PYLERA capsules are a combination antimicrobial product containing bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride for oral administration. Each size 0 elongated capsule contains:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>bismuth subcitrate potassium, 140 mg</item>
                     <item>metronidazole, 125 mg</item>
                     <item>smaller capsule (size 3) containing tetracycline hydrochloride, 125 mg</item>
                  </list>
                  <paragraph>Tetracycline hydrochloride is encapsulated within a smaller capsule to create a barrier to avoid contact with bismuth subcitrate potassium.</paragraph>
                  <paragraph>Each PYLERA capsule contains the following inactive ingredients: Magnesium Stearate NF, Lactose Monohydrate NF, Talc USP, Gelatin USP, and Titanium Dioxide NF, Printed in red ink.</paragraph>
                  <paragraph>Bismuth subcitrate potassium is a white or almost white powder. It is a soluble, complex bismuth salt of citric acid. The schematized empirical molecular formula of bismuth subcitrate potassium is Bi (Citrate)<sub>2</sub>K<sub>5</sub>∙3 H<sub>2</sub>O. The equivalent theoretical molecular formula is BiC<sub>12</sub>H<sub>14</sub>K<sub>5</sub>O<sub>17</sub>. The molecular mass of the theoretical molecular formula of a single unit of bismuth subcitrate potassium is 834.71. Metronidazole is a white to pale yellow crystalline powder. Metronidazole is 2-methyl-5-nitroimidazole-1-ethanol, with a molecular formula of C<sub>6</sub>H<sub>9</sub>N<sub>3</sub>O<sub>3</sub> and the following structural formula: </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="center" valign="bottom"/>
                     <tbody>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM1"/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <paragraph>Molecular weight: 171.2</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Tetracycline hydrochloride is a yellow, odorless, crystalline powder. Tetracycline hydrochloride is stable in air, but exposure to strong sunlight causes it to darken. Tetracycline hydrochloride is (4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-penta-hydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrochloride, with a molecular formula of C<sub>22</sub>H<sub>24</sub>N<sub>2</sub>O<sub>8</sub>∙HCl and the following structural formula:</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="center" valign="bottom"/>
                     <tbody>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM2"/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <paragraph>Molecular weight: 480.90</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20240430"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="pylera-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM2">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="pylera-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="8757025e-bdba-4265-aff5-9098048312dc"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250407"/>
               <component>
                  <section ID="S12.1">
                     <id root="334ba2b9-cb98-4229-8cd2-d8daed9b1d72"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1	Mechanism of Action</title>
                     <text>
                        <paragraph>PYLERA is a combination of antibacterial agents (metronidazole and tetracycline hydrochloride) and bismuth subcitrate potassium <content styleCode="italics">[see <linkHtml href="#S12.4">Microbiology (12.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="51ae953e-819d-426f-a9eb-864ca2887d48"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The pharmacokinetics of the individual components of PYLERA, bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride are summarized below.  In addition, two studies on PYLERA were conducted to determine the effect of co-administration on the pharmacokinetics of the components.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                     <component>
                        <section>
                           <id root="95477545-bbec-494f-a2d5-a7ff81f224b2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Bismuth Subcitrate Potassium (Bismuth)</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250407"/>
                           <component>
                              <section>
                                 <id root="b16f7c69-8817-49c1-a893-d4e552599c8b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Absorption and Distribution</content>
                                    </paragraph>
                                    <paragraph>Orally absorbed bismuth is distributed throughout the entire body. Bismuth is highly bound to plasma proteins (&gt;90%).</paragraph>
                                 </text>
                                 <effectiveTime value="20250407"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="50863b57-3fd3-4bd1-928b-7d9eff5e8024"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism and Excretion</content>
                                    </paragraph>
                                    <paragraph>The elimination half-life of bismuth is approximately 5 days in both blood and urine.  Elimination of bismuth is primarily through urinary and biliary routes. The rate of renal elimination appears to reach steady state 2 weeks after treatment discontinuation with similar rates of elimination at 6 weeks after discontinuation. The average urinary elimination of bismuth is 2.6% per day in the first two weeks after discontinuation (urine drug concentrations 24 to 250 mcg/mL) suggesting tissue accumulation and slow elimination.</paragraph>
                                 </text>
                                 <effectiveTime value="20250407"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="9806ed0d-ec0e-4635-baea-d6f7ce929935"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Metronidazole</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250407"/>
                           <component>
                              <section>
                                 <id root="8691aa4b-7644-4ec8-bc7c-10a7fc471c6e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Absorption and Distribution</content>
                                    </paragraph>
                                    <paragraph>Following oral administration, metronidazole is well absorbed, with peak plasma concentrations occurring between 1 and 2 hours after administration. Plasma concentrations of metronidazole are proportional to the administered dose, with oral administration of 500 mg producing a peak plasma concentration of 12 mcg/mL.</paragraph>
                                    <paragraph>Metronidazole appears in the plasma mainly as unchanged compound with lesser quantities of the 2-hydroxymethyl metabolite also present. Less than 20% of the circulating metronidazole is bound to plasma proteins. Metronidazole also appears in cerebrospinal fluid, saliva, and breast milk in concentration similar to those found in plasma.</paragraph>
                                 </text>
                                 <effectiveTime value="20250407"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="d502c5f5-a391-47f1-ae6b-c405ac2eeaa6"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism and Excretion</content>
                                    </paragraph>
                                    <paragraph>The average elimination half-life of metronidazole in normal volunteers is 8 hours.  The major route of elimination of metronidazole and its metabolites is via the urine (60% to 80% of the dose), with fecal excretion accounting for 6% to 15% of the dose. The metabolites that appear in the urine result primarily from side-chain oxidation [1-(β-hydroxyethyl) 2-hydroxymethyl-5-nitroimidazole and 2-methyl-5-nitroimidazole-1-yl-acetic acid] and glucuronide conjugation, with unchanged metronidazole accounting for approximately 20% of the total. Renal clearance of metronidazole is approximately 10 mL/min/1.73m<sup>2</sup>.</paragraph>
                                    <paragraph>Decreased renal function does not alter the single dose pharmacokinetics of metronidazole. In patients with decreased liver function, plasma clearance of metronidazole is decreased.</paragraph>
                                 </text>
                                 <effectiveTime value="20250407"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="659bd41a-bd6c-4470-988c-650d01f95183"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Tetracycline Hydrochloride</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                           <component>
                              <section>
                                 <id root="c179915c-2e27-4982-9cdc-d8dde34ad83c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Absorption, Distribution, Metabolism and Excretion</content>
                                    </paragraph>
                                    <paragraph>Tetracycline hydrochloride is absorbed (60%-90%) in the stomach and upper small intestine. The presence of food, milk or cations may significantly decrease the extent of absorption. In the plasma, tetracycline is bound to plasma proteins in varying degrees. It is concentrated by the liver in the bile and excreted in the urine and feces at high concentrations in biologically active form.</paragraph>
                                    <paragraph>Tetracycline hydrochloride is distributed into most body tissues and fluids. It is distributed into the bile and undergoes varying degrees of enterohepatic recirculation. Tetracycline hydrochloride tends to localize in tumors, necrotic or ischemic tissue, liver and spleen and form tetracycline-calcium orthophosphate complexes at sites of new bone formation or tooth development. Tetracycline readily crosses the placenta and is excreted in high amounts in breast milk.</paragraph>
                                 </text>
                                 <effectiveTime value="20240430"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="1fcd1311-37f0-47d6-9bb9-4d302bc3f61d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">PYLERA Capsules</content>
                              </paragraph>
                              <paragraph>A comparative bioavailability study of metronidazole (375 mg), tetracycline hydrochloride (375 mg) and bismuth subcitrate potassium (420 mg, equivalent to 120 mg Bi<sub>2</sub>O<sub>3</sub>) administered as PYLERA or as 3 separate capsule formulations administered simultaneously was conducted in healthy male volunteers. The pharmacokinetic parameters for the individual drugs, when administered as separate capsule formulations or as PYLERA, are similar as shown in <content styleCode="bold">Table 3</content>.</paragraph>
                              <table width="100%">
                                 <caption>Table 3: Mean (%CV) Pharmacokinetic Parameters for Metronidazole, Tetracycline hydrochloride, and Bismuth Subcitrate Potassium in Healthy Volunteers (N=18) </caption>
                                 <tfoot>
                                    <tr>
                                       <td colspan="5">*PYLERA given as a single dose of 3 capsules<br/>**C.V. – Coefficient Variation</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Lrule Rrule Toprule Botrule"/>
                                       <td styleCode="Lrule Rrule Toprule Botrule"/>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">
                                          <content styleCode="bold">C<sub>max</sub>
                                          </content>
                                          <br/>
                                          <content styleCode="bold">(ng/mL)</content>
                                          <br/>
                                          <content styleCode="bold">(%C.V.**)</content>
                                       </td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">
                                          <content styleCode="bold">AUC<sub>T</sub> (ng ∙ h/mL)</content>
                                          <br/>
                                          <content styleCode="bold">(%C.V.**)</content>
                                       </td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">
                                          <content styleCode="bold">AUC<sub>∞</sub>(ng ∙ h/mL)</content>
                                          <br/>
                                          <content styleCode="bold">(%C.V.**)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">
                                          <content styleCode="bold">Metronidazole</content>
                                       </td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">Metronidazole Capsule</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">9044 (20)</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">80289 (15)</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">81849 (16)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule Toprule Botrule"/>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">PYLERA*</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">8666.3 (22)</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">83018 (17)</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">84413 (17)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">
                                          <content styleCode="bold">Tetracycline</content>
                                       </td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">Tetracycline Capsules</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">748.0 (40)</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">9544 (55)</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">9864 (53)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule Toprule Botrule"/>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">PYLERA*</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">774 (47)</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">9674 (50)</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">9987 (49)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">
                                          <content styleCode="bold">Bismuth</content>
                                       </td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">Bismuth Capsule</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">22 (123)</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">47 (129)</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">65.4 (113)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule Toprule Botrule"/>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">PYLERA*</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">17 (202)</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">43 (191)</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">57 (178)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph/>
                           </text>
                           <effectiveTime value="20250407"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="a2aee129-cded-4296-8817-d29e1386486b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Effect of Bismuth on the Bioavailability of Tetracycline Hydrochloride</content>
                              </paragraph>
                              <paragraph>There is an anticipated reduction in tetracycline hydrochloride systemic absorption due to an interaction with bismuth.  The effect of a reduced tetracycline hydrochloride systemic exposure, due to an interaction with bismuth, on the clinical efficacy of PYLERA is not thought to be clinically meaningful as the contribution of systemic, as compared to local, antimicrobial activity against <content styleCode="italics">Helicobacter pylori</content> has not been established.</paragraph>
                           </text>
                           <effectiveTime value="20250407"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="e01931e8-7c12-443e-906f-eaf41da1a293"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Effect of Food on the Bioavailability of PYLERA</content>
                              </paragraph>
                              <paragraph>The pharmacokinetic parameters for metronidazole, tetracycline hydrochloride and bismuth were also determined when PYLERA was administered under fasting and fed conditions, as shown in <content styleCode="bold">Table 4</content>. Food reduced the systemic absorption of all three PYLERA components, with AUC values for metronidazole, tetracycline hydrochloride and bismuth being reduced by 6%, 34% and 60%, respectively. Reduction in the absorption of all three PYLERA components in the presence of food is not considered to be clinically significant. PYLERA should be given after meals and at bedtime, in combination with omeprazole twice a day.</paragraph>
                              <table width="100%">
                                 <caption> Table 4: Mean PYLERA Pharmacokinetic Parameters in Fasted and Fed States (N=18)*</caption>
                                 <tfoot>
                                    <tr>
                                       <td colspan="7">*PYLERA given as a single dose of 3 capsules<br/>**T<sub>max</sub> is expressed as median (range)</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Lrule Rrule Toprule Botrule"/>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center" colspan="3">
                                          <content styleCode="bold">FED</content>
                                       </td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center" colspan="3">
                                          <content styleCode="bold">FASTED</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule Toprule Botrule"/>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">
                                          <content styleCode="bold">metronidazole</content>
                                       </td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">
                                          <content styleCode="bold">tetracycline</content>
                                       </td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">
                                          <content styleCode="bold">bismuth</content>
                                       </td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">
                                          <content styleCode="bold">metronidazole</content>
                                       </td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">
                                          <content styleCode="bold">tetracycline</content>
                                       </td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">
                                          <content styleCode="bold">bismuth</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">
                                          <content styleCode="bold">C<sub>max</sub>
                                          </content>
                                          <br/>
                                          <content styleCode="bold">(ng/mL)</content>
                                          <br/>
                                          <content styleCode="bold">(%C.V.)</content>
                                       </td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">6835.0<br/>(13)</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">515.8<br/>(36)</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">1.7<br/>(61)</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">8666.3<br/>(22)</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">773.8<br/>(47)</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">16.7<br/>(202)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">
                                          <content styleCode="bold">T<sub>max</sub>
                                          </content>
                                          <br/>
                                          <content styleCode="bold">(hours)**</content>
                                          <br/>
                                          <content styleCode="bold">(range)</content>
                                       </td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">3.0<br/>(1.3 – 4.0)</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">4.0<br/>(2.5 – 5.0)</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">3.5<br/>(0.8 – 6.0)</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">0.75<br/>(0.5 – 3.5)</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">3.3<br/>(1.3 – 5.0)</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">0.6<br/>(0.5 – 1.7) </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">
                                          <content styleCode="bold">AUC<sub>∞</sub>
                                          </content>
                                          <br/>
                                          <content styleCode="bold">(ng ∙ h/mL)</content>
                                          <br/>
                                          <content styleCode="bold">(%C.V.)</content>
                                       </td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">79225.6<br/>(18)</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">5840.1<br/>(312)</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">18.4<br/>(116)</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">84413.6<br/>(17)</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">9986.7<br/>(49)</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" align="center">56.5<br/>(178)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph/>
                           </text>
                           <effectiveTime value="20250407"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="150402ac-4686-4356-82a8-d82512f6af07"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Effect of Omeprazole on the Bioavailability of Bismuth</content>
                              </paragraph>
                              <paragraph>The effect of omeprazole on bismuth absorption was assessed in 34 healthy volunteers given PYLERA (four times daily) with or without omeprazole (20 mg twice daily) for 6 days. In the presence of omeprazole, the extent of absorption of bismuth from PYLERA was significantly increased, compared to when no omeprazole was given (<content styleCode="bold">Table 5</content>). Concentration-dependent neurotoxicity is associated with long-term use of bismuth and not likely to occur with short-term administration or at steady state concentrations below 50 ng/mL. One subject transiently achieved a maximum bismuth concentration (C<sub>max</sub>) higher than 50 ng/mL (73 ng/mL) following multiple dosing of PYLERA with omeprazole. The patient did not exhibit symptoms of neurotoxicity during the study. There is no clinical evidence to suggest that short-term exposure to bismuth C<sub>max</sub> concentrations above 50 ng/mL is associated with neurotoxicity.</paragraph>
                              <table width="100%">
                                 <caption> Table 5: Mean Bismuth Pharmacokinetic Parameters following PYLERA Administration* With and Without Omeprazole (N=34)</caption>
                                 <tfoot>
                                    <tr>
                                       <td colspan="5">*PYLERA given as 3 capsules four times daily for 6 days with or without 20 mg omeprazole twice daily<br/>**C.V. – Coefficient Variation</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Lrule Rrule Toprule">
                                          <content styleCode="bold">Parameter</content>
                                       </td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" colspan="2">
                                          <content styleCode="bold">Without omeprazole</content>
                                       </td>
                                       <td styleCode="Lrule Rrule Toprule Botrule" colspan="2">
                                          <content styleCode="bold">With omeprazole</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule Botrule"/>
                                       <td styleCode="Lrule Rrule Toprule Botrule">
                                          <content styleCode="bold">Mean</content>
                                       </td>
                                       <td styleCode="Lrule Rrule Toprule Botrule">
                                          <content styleCode="bold">%C.V.**</content>
                                       </td>
                                       <td styleCode="Lrule Rrule Toprule Botrule">
                                          <content styleCode="bold">Mean</content>
                                       </td>
                                       <td styleCode="Lrule Rrule Toprule Botrule">
                                          <content styleCode="bold">%C.V.**</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule Toprule Botrule">
                                          <content styleCode="bold">C<sub>max</sub> (ng/mL)</content>
                                       </td>
                                       <td styleCode="Lrule Rrule Toprule Botrule">8.1</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule">84</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule">25.5</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule">69</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule Toprule Botrule">
                                          <content styleCode="bold">AUC<sub>T</sub> (ng ∙ h/mL)</content>
                                       </td>
                                       <td styleCode="Lrule Rrule Toprule Botrule">48.5</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule">28</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule">140.9</td>
                                       <td styleCode="Lrule Rrule Toprule Botrule">42</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph/>
                           </text>
                           <effectiveTime value="20250407"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.4">
                     <id root="68bde694-276a-4433-83e6-eaabf5169d87"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4 Microbiology</title>
                     <effectiveTime value="20240430"/>
                     <component>
                        <section>
                           <id root="d117b303-9b6c-4097-b351-ea695b333afc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mechanism of Action</content>
                              </paragraph>
                              <paragraph>PYLERA is a combination of antibacterial agents (metronidazole and tetracycline hydrochloride) and bismuth subcitrate potassium.  Tetracycline hydrochloride interacts with the 30S subunit of the bacterial ribosome and inhibits protein synthesis.  Metronidazole's  antibacterial mechanism of action in an anaerobic environment is not fully understood but a possible mechanism includes reduction by intracellular electron transport proteins after entry into the organism.  Because of this alteration to the metronidazole molecule, a concentration gradient is created and maintained which promotes the drug's intracellular transport. Presumably, free radicals are formed which, in turn, react with cellular components resulting in death of bacteria. The antibacterial action of bismuth salts is not well understood.</paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="80315f69-7fc2-4018-8103-92f1de9ba1cf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Antimicrobial Activity</content>
                              </paragraph>
                              <paragraph>PYLERA plus omeprazole therapy has been shown to be active against most isolates of <content styleCode="italics">Helicobacter pylori</content> both <content styleCode="italics">in vitro</content> and in clinical infections <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3d7ccfb1-10fa-455d-a852-906d80a97076"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Susceptibility Testing</content>
                              </paragraph>
                              <paragraph>For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.</paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="fec68290-8358-49e6-b282-a1933e69d70a"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20240430"/>
               <component>
                  <section ID="S13.1">
                     <id root="4a4879c6-691f-4623-99ca-99f73b847fbf"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>No long-term studies have been performed to evaluate the effect of PYLERA on carcinogenesis, mutagenesis, or impairment of fertility.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                     <component>
                        <section>
                           <id root="7a067d08-d4b6-43d0-afd3-652d2e291995"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Bismuth Subcitrate Potassium</content>
                              </paragraph>
                              <paragraph>No carcinogenicity or reproductive toxicity studies have been conducted with bismuth subcitrate potassium. Bismuth subsalicylate did not show mutagenic potential in the NTP <content styleCode="italics">Salmonella</content> plate assay.</paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="739297a4-83e7-4497-aea8-bc6969e62495"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Metronidazole</content>
                              </paragraph>
                              <paragraph>Metronidazole has shown evidence of carcinogenic activity in a number of studies involving chronic, oral administration in mice and rats. Prominent among the effects in the mouse was an increased incidence of pulmonary tumorigenesis. This has been observed in all six reported studies in that species, including one study in which the animals were dosed on an intermittent schedule (administration during every fourth week only). At the highest dose levels, (approximately 500 mg/kg/day, which is approximately 1.6 times the indicated human dose for a 60 kg adult based on body surface area) there was a statistically significant increase in the incidence of malignant liver tumors in male mice. Also, the published results of one of the mouse studies indicate an increase in the incidence of malignant lymphomas as well as pulmonary neoplasms associated with lifetime feeding of the drug. All these effects are statistically significant. Long-term, oral-dosing studies in the rat showed statistically significant increases in the incidence of various neoplasms, particularly in mammary and hepatic tumors, among female rats administered metronidazole over those noted in the concurrent female control groups. Two lifetime tumorigenicity studies in hamsters have been performed and reported to be negative. Although metronidazole has shown mutagenic activity in a number of <content styleCode="italics">in vitro</content> assay systems, studies in mammals (<content styleCode="italics">in vivo</content>) have failed to demonstrate a potential for genetic damage.</paragraph>
                              <paragraph>Fertility studies have been conducted with male rats and mice with divergent results. Metronidazole, at doses up to 400 mg/kg/day (approximately 3 times the indicated human dose based on mg/m<sup>2</sup>) for 28 days, failed to produce any adverse effects on fertility and testicular function in male rats. Rats treated with up to 400 mg/kg/day for 6 weeks or longer, showed severe degeneration of the seminiferous epithelium in the testes which was associated with a marked decrease in testicular spermatid counts and epididymal sperm counts and a marked decrease in fecundity.  These effects were partially reversible.</paragraph>
                              <paragraph>Fertility studies have been performed in male mice at doses up to six times the maximum recommended human dose based upon mg/m<sup>2</sup> and have revealed no evidence of impaired fertility. Another fertility study was performed in male mice at oral doses of 500 mg/kg/day (approximately 2 times the indicated human dose based on mg/m<sup>2</sup>) for 14 days.  Metronidazole significantly decreased testes and epididymides weight, decreased sperm viability, and increased the incidence of abnormal sperm.  The viability of sperm was normal by 2 months after the start of the treatment.</paragraph>
                              <paragraph>Tumors affecting the liver, lungs, mammary, and lymphatic tissues have been detected in several studies of metronidazole in rats and mice, but not hamsters.</paragraph>
                              <paragraph>Pulmonary tumors have been observed in all six reported studies in the mouse, including one study in which the animals were dosed on an intermittent schedule (administration during every fourth week only). Malignant liver tumors were increased in male mice treated at approximately 1500 mg/m<sup>2</sup> (similar to the maximum recommended daily dose, based on body surface area comparisons). Malignant lymphomas and pulmonary neoplasms were also increased with lifetime feeding of the drug to mice. Mammary and hepatic tumors were increased among female rats administered oral metronidazole compared to concurrent controls. Two lifetime tumorigenicity studies in hamsters have been performed and reported to be negative.</paragraph>
                              <paragraph>Metronidazole has shown mutagenic activity in <content styleCode="italics">in vitro</content> assay systems including the Ames test. Studies in mammals <content styleCode="italics">in vivo</content> have failed to demonstrate a potential for genetic damage.</paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="cd52049d-f281-4a97-89fd-31833f270f4d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Tetracycline hydrochloride</content>
                              </paragraph>
                              <paragraph>There has been no evidence of carcinogenicity for tetracycline hydrochloride in studies conducted with rats and mice. Some related antibiotics (oxytetracycline, minocycline) have shown evidence of oncogenic activity in rats.</paragraph>
                              <paragraph>There was evidence of mutagenicity by tetracycline hydrochloride in two <content styleCode="italics">in vitro</content> mammalian cell assay systems (L51784y mouse lymphoma and Chinese hamster lung cells).</paragraph>
                              <paragraph>Tetracycline hydrochloride had no effect on fertility when administered in the diet to male and female rats at a daily intake of 25 times the human dose.</paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="395c956c-0dde-4efd-85bc-8c615e1ade6e"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20250407"/>
               <component>
                  <section ID="L029b06ec-613b-4a9d-bc8a-283cb729d204">
                     <id root="95d04887-c17c-4d92-8d0b-f4a2e48be7c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Eradication of <content styleCode="italics">Helicobacter pylori</content> in Patients with Active Duodenal Ulcer or History of Duodenal Ulcer Disease</title>
                     <text>
                        <paragraph>An open-label, parallel group, active-controlled, multicenter study in <content styleCode="italics">Helicobacter pylori</content> positive patients with current duodenal ulcer or a history of duodenal ulcer disease was conducted in the United States and Canada (the North American Study).</paragraph>
                        <paragraph>Patients were randomized to one of the following 10-day treatment regimens:</paragraph>
                        <list listType="unordered">
                           <item>Three (3) PYLERA capsules four times daily, after meals and at bedtime plus 20 mg omeprazole twice a day after the morning and evening meals (OBMT).</item>
                           <item>Clarithromycin 500 mg plus 1000 mg amoxicillin plus 20 mg omeprazole twice a day before the morning and evening meals (OAC).</item>
                        </list>
                        <paragraph>
                           <content styleCode="italics">H. pylori</content> eradication rates, defined as two negative <sup>13</sup>C-urea breath tests performed at 4 and 8 weeks post-therapy are shown in <content styleCode="bold">Table 6</content> for OBMT and OAC. The eradication rates for both groups were found to be similar using either the Per Protocol (PP) or Modified Intent-to-Treat (MITT) populations.</paragraph>
                        <table width="100%">
                           <caption>Table 6: Helicobacter pylori Eradication at 8 Weeks after 10 Day Treatment Regimen Percent (%) of Patients Cured [95% Confidence Interval] (Number of Patients)</caption>
                           <tfoot>
                              <tr styleCode="First Last">
                                 <td colspan="4">*<content styleCode="bold">OBMT</content>: Omeprazole + PYLERA (bismuth subcitrate potassium / metronidazole / tetracycline hydrochloride)<br/>**<content styleCode="bold">OAC</content>: Omeprazole + amoxicillin + clarithromycin<br/>
                                    <sup>a</sup> Patients were included in the PP analysis if they had <content styleCode="italics">H. pylori</content> infection documented at baseline, defined as a positive <sup>13</sup>C-UBT plus histology or culture, had at least one endoscopically verified duodenal ulcer ≥ 0.3 cm at baseline or had a documented history of duodenal ulcer disease, and were not protocol violators. Additionally, if patients dropped out of the study due to an adverse event related to the study drug, they were included in the evaluable analysis as failures of therapy.<br/>
                                    <sup>b</sup> Patients were included in the MITT analysis if they had documented <content styleCode="italics">H. pylori</content> infection at baseline as defined above, and had at least one documented duodenal ulcer at baseline or had a documented history of duodenal ulcer disease, and took at least one dose of study medication. All dropouts were included as failures of therapy.<br/>
                                    <sup>c</sup> Results for OAC treatment represent all isolates regardless of clarithromycin susceptibility. Eradication rates for clarithromycin susceptible organisms, as defined by an MIC ≤ 0.25 mcg/mL, were 94.6% and 92.1% for the PP and MITT analysis, respectively. Eradication rates for clarithromycin non-susceptible organisms, as defined by an MIC ≥ 0.5 mcg/mL, were 23.1% and 21.4% for the PP and MITT analysis, respectively.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule"/>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="2" align="center">
                                    <content styleCode="bold">​Treatment Group</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">​Difference</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule"/>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">OBMT</content>*</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">OAC</content>** <sup>c</sup>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">Per Protocol<sup>a</sup>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">92.5%<br/>[87.8, 97.2]<br/>(n=120)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">85.7%<br/>[76.9, 91.8]<br/>(n=126)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">6.8%<br/>[-0.9, 14.5]</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">Modified<br/>Intent-to-Treat<sup>b</sup>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">87.7%<br/>[82.2, 93.2]<br/>(n=138)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">83.2%<br/>[77.0, 89.5]<br/>(n=137)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">4.5%<br/>[-3.9, 12.8]</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="8c17f9fc-1d4f-49d4-87e7-0b51fca72d99"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>PYLERA is supplied as a white opaque capsule containing 140 mg bismuth subcitrate potassium, 125 mg metronidazole, and 125 mg tetracycline hydrochloride, with the APTALIS<sub>™</sub> logo printed on the body and "BMT" printed on the cap. PYLERA capsules are supplied as the 10 day Therapy pack containing 10 blister cards, with each card containing 12 PYLERA capsules for a total of 120 capsules.</paragraph>
                  <paragraph>NDC Number: 61269-380-12, Blister pack of 120.</paragraph>
               </text>
               <effectiveTime value="20250407"/>
               <component>
                  <section>
                     <id root="2b2c707e-aaba-4f4a-b239-44a51adc010c"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Storage</content>
                        </paragraph>
                        <paragraph>Store at controlled room temperature [68° to 77°F or 20° to 25°C].</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="0ed75428-3f9d-414d-8f6c-8187b732cced"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <effectiveTime value="20250407"/>
               <component>
                  <section>
                     <id root="cb88916d-801d-4e55-8810-e952130b6777"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>
                        </paragraph>
                        <paragraph>Advise the lactating women to pump and discard their milk during treatment with PYLERA and for 2 days after the therapy ends <content styleCode="italics">[see <linkHtml href="#S8.2">Use in Specific Populations (8.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="77e4f3a9-2146-46f2-a3d0-2028b9039939"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hypersensitivity</content>
                        </paragraph>
                        <paragraph>Inform patients that PYLERA may cause allergic reactions and to discontinue PYLERA at the first sign of urticaria, erythematous rash, flushing, and fever or other symptoms of an allergic reaction <content styleCode="italics">[see <linkHtml href="#S4.7">Contraindications (4.6)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="4c1d1213-1aad-4c55-8f70-5cf7fb42519a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Severe Cutaneous Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Advise patients that PYLERA capsules may increase the risk of serious and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis (TEN), Stevens- Johnson syndrome (SJS), and drug reaction with eosinophilia and systemic symptoms (DRESS). Instruct the patient to be alert for skin rash, blisters, fever or other signs and symptoms of these hypersensitivity reactions. Advise patients to stop PYLERA capsules immediately if they develop any type of rash and seek medical attention [<content styleCode="italics">see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="66ad03dc-9ae7-4b4e-a1cb-205ea475129f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Central Nervous System Effects</content>
                        </paragraph>
                        <paragraph>Inform patients of the risk of central and peripheral nervous system effects with PYLERA and to discontinue PYLERA and report immediately to their health-care provider if any neurologic symptoms occur <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="c0657fb9-9b08-41a1-8d55-d9db65490260"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Photosensitivity</content>
                        </paragraph>
                        <paragraph>Avoid exposure to sun or sun lamps while taking PYLERA <content styleCode="italics">[see <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="e6d293e4-0e45-4045-90ab-26c1d398291c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Drug Interactions</content>
                        </paragraph>
                        <paragraph>Advise patients to report to their health-care provider the use of any other medications while taking PYLERA. The administration of any of the following drugs with PYLERA may result in clinically significant adverse reactions or insufficient drug efficacies <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml> and <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>:</paragraph>
                        <paragraph/>
                        <list listType="unordered" styleCode="Disc">
                           <item>Disulfiram</item>
                           <item>Alcoholic Beverages, or Products Containing Propylene Glycol</item>
                           <item>Oral Contraceptives</item>
                           <item>Anticoagulants</item>
                           <item>Lithium</item>
                           <item>Antacids, Multivitamins, or Dairy Products</item>
                           <item>Busulfan</item>
                           <item>Cimetidine</item>
                           <item>Phenytoin and Phenobarbital</item>
                        </list>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="994ec359-fca5-4660-8efa-44bdcafdd12b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Darkening of the Tongue and/or Stool</content>
                        </paragraph>
                        <paragraph>Inform patients that PYLERA may cause temporary and harmless darkening of the tongue and/or black stool generally reversible within several days after treatment is stopped. Stool darkening should not be confused with melena (blood in the stool) <content styleCode="italics">[see <linkHtml href="#S5.9">Warnings and Precautions (5.9)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="7b237fae-a4fa-41b5-bf4f-c36c9a587ae4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Dosing Information</content>
                        </paragraph>
                        <paragraph>Inform patients that each dose of PYLERA includes 3 capsules. All 3 capsules should be taken 4 times a day (after meals and at bedtime) for 10 days. One omeprazole 20 mg capsule should be taken twice a day with PYLERA after the morning and evening meal for 10 days.</paragraph>
                        <paragraph>If a dose is missed, advise patient not to make up the dose, but to continue the normal dosing schedule until medication is gone.  Patients should not take double doses. If more than 4 doses are missed, advise the patient to contact their health-care provider <content styleCode="italics">[see <linkHtml href="#S2">Dosage and Administration (2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="f03002bc-b9a1-4dfe-b05e-4551b569a781"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Administration with Fluids</content>
                        </paragraph>
                        <paragraph>Instruct patients to swallow the PYLERA capsules whole with a full glass of water (8 ounces).  Ingestion of adequate amounts of fluid, particularly with the bedtime dose, is recommended to reduce the risk of esophageal irritation and ulceration by tetracycline hydrochloride <content styleCode="italics">[see <linkHtml href="#S2">Dosage and Administration (2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="f92589a3-2032-4af3-9ccf-bd70365ff1a5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Antibacterial Resistance</content>
                        </paragraph>
                        <paragraph>Patients should be counseled that antibacterial drugs including PYLERA should only be used to treat bacterial infections.  They do not treat viral infections (e.g., the common cold).  When PYLERA is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed.  Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by PYLERA or other antibacterial drugs in the future.</paragraph>
                     </text>
                     <effectiveTime value="20250407"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="3746e8e5-f1ac-4b10-8586-bd86311d66d9"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Distributed By:</content>
                     <br/>H2-Pharma, LLC<br/>Montgomery, AL 36117</paragraph>
                  <paragraph>PYLERA® is a registered trademark of Laboratoires Juvisé Pharmaceuticals.</paragraph>
                  <paragraph>v4.0USPI380</paragraph>
               </text>
               <effectiveTime value="20250407"/>
            </section>
         </component>
         <component>
            <section>
               <id root="e28f2674-95e8-4599-9dd7-b802f805c868"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 120 Capsule Blister Card Box</title>
               <text>
                  <paragraph>NDC 61269-380-12</paragraph>
                  <paragraph>120 Capsules in 10 blister cards<br/>Each card contains 4 blisters.<br/>Each blister contains 3 capsules.</paragraph>
                  <paragraph>PYLERA<sup>®</sup>
                     <br/>CAPSULES</paragraph>
                  <paragraph>(bismuth subcitrate potassium 140 mg,<br/>metronidazole 125 mg, tetracycline HCl 125 mg)</paragraph>
                  <paragraph>
                     <content styleCode="bold">10 Day Therapy PAK</content>
                  </paragraph>
                  <paragraph>Rx only<br/>Combination therapy indicated for the eradication of Heliobacter pylori</paragraph>
                  <paragraph>
                     <content styleCode="bold">One blister card = 1 day of therapy</content>
                  </paragraph>
                  <paragraph>JUVISE<sup>®</sup>
                     <br/>pharmaceuticals</paragraph>
                  <paragraph>See directions for opening on bottom of the box. </paragraph>
                  <paragraph>Directions: Insert two fingers and pull out flap. Remove and discard the perforated window. Take one blister pack each day for 10 days.</paragraph>
                  <paragraph>Combination therapy indicated for the treatment of patients with <content styleCode="italics">Helicobacter pylori</content> infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate <content styleCode="italics">H. pylori</content>
                  </paragraph>
                  <paragraph>NO VARNISH</paragraph>
                  <paragraph>301471-04</paragraph>
                  <paragraph>PYL-USA-1151</paragraph>
                  <paragraph>Distributed by: H2-Pharma, LLC</paragraph>
                  <paragraph>Mongomery, AL 36117</paragraph>
                  <paragraph>PYLERA<sup>®</sup> is a registered trademark of Laboratoires Juvise Pharmaceuticals.</paragraph>
                  <paragraph>Made in Canada.</paragraph>
                  <paragraph>JUVISE®</paragraph>
                  <paragraph>pharmaceuticals</paragraph>
                  <paragraph>(01) 0 0361269 38012 9</paragraph>
                  <paragraph>
                     <content styleCode="bold">Dosage:</content>
                  </paragraph>
                  <table width="100%">
                     <caption/>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule Botrule" align="center">
                              <content styleCode="bold">Time of Dose</content>
                           </td>
                           <td styleCode="Toprule Botrule" align="center">
                              <content styleCode="bold">​Number of capsules of PYLERA</content>
                              <sup>®</sup>
                           </td>
                           <td styleCode="Toprule Botrule" align="center">
                              <content styleCode="bold">​Number of capsules of omeprazole 20 mg</content>​*</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule">After morning meal</td>
                           <td styleCode="Toprule Botrule" align="center">3</td>
                           <td styleCode="Toprule Botrule" align="center">1</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule">After lunch</td>
                           <td styleCode="Toprule Botrule" align="center">3</td>
                           <td styleCode="Toprule Botrule" align="center">0</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule">After evening meal</td>
                           <td styleCode="Toprule Botrule" align="center">3</td>
                           <td styleCode="Toprule Botrule" align="center">1</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule"> At bedtime</td>
                           <td styleCode="Toprule Botrule" align="center">3</td>
                           <td styleCode="Toprule Botrule" align="center">0</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph> Each PYLERA<sup>® </sup>​Capsule contains bismuth subcitrate potassium 140 mg, metronidazole 125 mg, and tetracycline hydrochloride 125 mg and the following inactive ingredients: Magnesium Stearate NF, Lactose Monohydrate NF, Talc USP, Gelatin USP, and Titanium Dioxide NF.</paragraph>
                  <paragraph>PYLERA<sup>®</sup> is supplied as a white opaque capsule with Aptalis log printed on body and BMT printed on cap.</paragraph>
                  <paragraph>*PYLERA<sup>®</sup> Capsules do not contain omeprazole.</paragraph>
                  <paragraph>Store at controlled room temperature [68° to 77°F or 20° to 25°C].</paragraph>
                  <paragraph>
                     <content styleCode="bold">​Please see complete Prescribing Information including safety and warnings inside the box.</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20250407"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>PRINCIPAL DISPLAY PANEL - 120 Capsule Blister Card Box</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="pylera-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>